However, YTHDF2 expression is reversely correlated with the ICP genes in BLCA, BRCA, GBM, LUAD, LUSC, and THYM, suggesting a poor immunotherapy outcome in YTHDF2 overexpression patients with those tumors. This evidence concerns the gene YTHDF2 and glioblastoma.